Found 6 matching trials
Preclinical Safety Evaluation and First-in-Human Translational Study of [177Lu]Lu-TEFAPI-06 EARLY_PHASE1 This study aims to systematically evaluate the safety, biodistribution, dos...
Show More Location
The Second Hospital & Clinical Medical School, Lanzhou University
Learn More & Join Trial
Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors PHASE2 Increased fibroblast activation protein expression is positively correlated...
Show More Location
The First Affiliated Hospital of Xiamen University
Learn More & Join Trial
A Study to Evaluate the Safety and Efficacy of PRRT With 177Lu-EB-FAPI in Patients With Advanced Cholopancreatic Tumors PHASE1 This study is a prospective, single-center, open, single-arm, exploratory s...
Show More Location
First Affiliated Hospital of Zhejiang University
Learn More & Join Trial
177Lu-CTR-FAPI for the Treatment of Thyroid Cancer PHASE1 This is a multi-center, open-label, single-arm, dose-escalation phase I stu...
Show More Location
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Learn More & Join Trial
Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer PHASE1 Increased fibroblast activation protein expression is positively correlated...
Show More Location
The First Affiliated Hospital of Xiamen University
Learn More & Join Trial
177Lu-FAP-2286 Treatment in Urethelial Neoplasms: Utility and Safety as a Novel Treatment. PHASE2 Ga-68-FAPI has recently been proven to be superior to F-18-FDG in various c...
Show More Location
Multiple Locations
Learn More & Join Trial